Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy - MPR
Links shared publicly online about this topic.
- 1,403total visits
Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy - MPR
empr.com —
The FDA has notified healthcare professionals and patients that the risk of developing progressive multifocal leukoencephalopathy (PML) increases with the number of Tysabri (natalizumab, from Biogen Idec) infusions received.
View full resource at empr.com
Tags: Healthcare, FDA, Tysabri, Biogen Idec
Most Recently Shared on February 5, 2010 at 6:44 pm By:
MPR News: Tysabri labeling to include safety information on risk of progressive multifocal leukoencephalopathy: Th... http://bit.ly/9G7EQr
Advertisement
